Eckhardt Sue Gail sold $492K of EXEL

Eckhardt Sue Gail sold 9,812 shares of EXELIXIS, INC. (EXEL) at $50.14 ($0.49M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Eckhardt Sue Gail
Published Jun 3, 2026, 10:51 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 3, 2026, 10:56 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$EXEL
Neutral
medium confidence
Mentioned
$EXEL
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$EXELNeutralLow
01

Why it matters

The disclosure may slightly influence sentiment, but the presence of a pre-arranged 10b5-1 plan reduces interpretability as a new bearish fundamental view.

02

Market read

A routine 10b5-1 insider sale; potential for minor short-term sentiment noise rather than a catalyst.

03

What to watch

Director sales can be driven by diversification/tax planning; without changes in buying activity or new company fundamentals, the signal is limited.

Relevance 6/10Novelty 4/10Timing: Filed after-hours on 2026-06-03; sale executed 2026-06-01

Background

This is an SEC Form 4 insider transaction disclosure (director selling) for EXELIXIS, Inc.

Company-level read

Ticker impact

$EXELNeutralMedium confidence
Context

Director Eckhardt Sue Gail sold 9,812 EXELIXIS shares in an open-market transaction under a pre-arranged 10b5-1 plan.

Expected impact

Mild, short-lived negative-to-neutral sentiment impact; unlikely to drive a sustained move by itself.

Evidence & confidence

The filing is a routine 10b5-1 sale by a director with no accompanying operational or financial catalyst described.

Market effects

No direct sector read-through; this is company-specific insider transaction disclosure.

None.

None.

Counterpoint

If the market overweights insider selling, the 10b5-1 structure suggests the trade may be mechanical rather than a bearish signal.

Key entities

  • EXELIXIS, INC.

    Company whose director insider sale was reported on SEC Form 4.

  • Eckhardt Sue Gail

    Director who executed an open-market sale under a Rule 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$EXELMedAI 8/10

Exelixis (EXEL) Q3 2026 Earnings Call Transcript

Exelixis reported Q3 2026 revenues of $659M, with cabozantinib franchise U.S. net product revenues at $605M, up 11% YoY. Global revenues reached $818M. Zanzalintinib is a key growth driver, with multiple trials advancing. GAAP net income was $218M ($0.88 per share). The company updated full-year guidance and repurchased $250M in stock.

$EXELMed

Exelixis Inc (EXEL) (Q3 2026) Earnings Call Highlights: CABOMETYX Momentum

Exelixis Inc (EXEL) reported Q3 2026 earnings, highlighting delays in zanzalintinib's PDUFA date to March 2027 and STELLAR-304 results to Q1 2027. Full-year 2026 revenue guidance was maintained but reflects reduced expectations due to temporal NET indication revenue. CABOMETYX sales grew 6% quarter-over-quarter, with gross-to-net deductions projected at 30%. The company addressed competition, clinical trials, and the 340B program's minimal impact.

$EXELMed

BMO raises Exelixis stock price target to $60 on OpEx outlook

BMO Capital raised Exelixis' (NASDAQ:EXEL) price target to $60 from $54, citing adjusted long-term operating expense assumptions. The stock trades near its 52-week high at $66.20, up 70% over the past year. Exelixis reported Q3 2026 earnings of $0.94 per share, beating estimates by 8.05%, with revenue of $658.69 million, a 1.81% beat. The company maintained its 2026 revenue guidance, attributing it to the gradual ramp of its NET product.